Stratagene's Q3 Revenue Slides 2 Percent as Invitrogen Damages Distend Losses | GenomeWeb
NEW YORK (GenomeWeb News) — Stratagene today said third-quarter revenues decreased 2 percent as an unfavorable court decision caused net losses to balloon 817 percent.
Total receipts for the three months ended Sept. 30 decreased to $23.2 million from $23.7 million year over year. The company blamed part of the slide on declining sales in its gene-discovery and cloning systems products.
R&D spending remained flat at around $2.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.